British Columbia Extends Biosimilar Switching To Adalimumab

Follows Launch Of Five Humira Biosimilars In Canada In February

British Columbia has expanded its biosimilar switching program to cover patients being treated with Humira in the Canadian province.

British Columbia Canada Flags
British Columbia is flying the flag for biosimilar switching in Canada • Source: Alamy

Patients being treated with Humira (adalimumab) in British Columbia will soon be switched to adalimumab biosimilars, after the Canadian province expanded its biosimilar switching program to cover the blockbuster biologic.

Almost two years ago, British Columbia launched its biosimilar switching program that saw patients being treated with etanercept, infliximab and...

More from Biosimilars

‘Our Position Has Naturally Shifted’ – How Standalone Sandoz Is Taking On Originator Abuses

 
• By 

As a standalone generics and biosimilars company, Sandoz now feels freer to speak out against originator abuses of intellectual property, the firm’s global IP head Julia Pike tells Generics Bulletin, including challenges to Bayer on rivaroxaban and Amgen on etanercept.

Kirsty Gives Biocon A First Interchangeable US Insulin Aspart Biosimilar

 
• By 

After years of waiting, Biocon Biologics has finally snagged US FDA approval for its insulin aspart biosimilar – along with a first designation of interchangeability. However, Sanofi’s Merilog version is already approved as a rival to Novo Nordisk’s Novolog.

Making The UK A Leading Biosimilar Launch Destination – Realistic Or Optimistic?

 

Experts discussed the UK government’s commitment to make the country a desirable destination for companies to launch their biosimilars at a recent conference hosted by Medicines UK.

Room For Improvement? EU Industry Prepares Feedback For SPC Manufacturing Waiver Review

 
• By 

As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.

More from Products

MSN’s Entresto Generic Temporarily Blocked As Key US Patent Expires

 
• By 

The Federal Circuit has temporarily blocked MSN from launching a generic version of Entresto, granting Novartis short-term relief while it reviews the company’s emergency Rule 8 motion for a longer injunction.

Making The UK A Leading Biosimilar Launch Destination – Realistic Or Optimistic?

 

Experts discussed the UK government’s commitment to make the country a desirable destination for companies to launch their biosimilars at a recent conference hosted by Medicines UK.

Room For Improvement? EU Industry Prepares Feedback For SPC Manufacturing Waiver Review

 
• By 

As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.